ethyl 7-(4-(trifluoromethyl)phenyl)-4-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate | 1160270-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 7-(4-(trifluoromethyl)phenyl)-4-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate
• 英文别名: Ethyl 7-(4-(trifluoromethyl)phenyl)-4-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate；ethyl 7-[4-(trifluoromethyl)phenyl]-4-(trifluoromethylsulfonyloxy)naphthalene-2-carboxylate
• CAS: 1160270-01-8
• 化学式: C₂₁H₁₄F₆O₅S
• 分子量: 492.396
• InChiKey: RORFPLGWWBDOPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  ethyl 7-(4-(trifluoromethyl)phenyl)-4-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 、 potassium acetate 、 potassium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 ethyl 4-(4-(piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate
  参考文献：
  名称：

  Exploration of Alternative Scaffolds for P2Y₁₄ Receptor Antagonists Containing a Biaryl Core

  摘要：

  Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y(14) receptor (P2Y(14)R) antagonists were synthesized, and affinity was measured in P2Y(14)R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y(14)R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 approximate to 20 nM at hP2Y(14)R/mP2Y(14)R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y(14)R antagonist structure-activity relationship, introducing diverse physical-chemical properties.

  DOI：

  10.1021/acs.jmedchem.0c00745
• 作为产物：
  描述：

  7-溴-4-羟基-2-萘羧酸乙酯 在 吡啶 、 sodium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.5h， 生成 ethyl 7-(4-(trifluoromethyl)phenyl)-4-(((trifluoromethyl)sulfonyl)oxy)-2-naphthoate
  参考文献：
  名称：

  A Selective High-Affinity Antagonist of the P2Y₁₄ Receptor Inhibits UDP-Glucose–Stimulated Chemotaxis of Human Neutrophils

  摘要：

  1

  DOI：

  10.1124/mol.113.085654

文献信息

• [EN] SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY<br/>[FR] ACIDES 2-NAPHTOÏQUE SUBSTITUÉS EN TANT QU'ANTAGONISTES DE L'ACTIVITÉ DE GPR105
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009070873A1

  公开（公告）日：2009-06-11

  Substituted 2-naphthoic acids of structural formula I are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.

  结构式I中的2-萘甲酸替代物对GPR105蛋白的生物活性具有拮抗作用。它们可用于治疗、控制或预防对该受体拮抗有响应的疾病，如糖尿病，特别是2型糖尿病，胰岛素抵抗，高血糖，脂质紊乱，肥胖，动脉粥样硬化以及与代谢综合征相关的疾病。
• Structure-Guided Modification of Heterocyclic Antagonists of the P2Y₁₄ Receptor
  作者：Jinha Yu、Antonella Ciancetta、Steven Dudas、Sierra Duca、Justine Lottermoser、Kenneth A. Jacobson

  DOI：10.1021/acs.jmedchem.8b00168

  日期：2018.6.14

  persistence of ligand-protein interactions over time. Predictions of a favorable substitution of a 5-phenyl group with thiophene and an insertion of a three-methylene spacer between the 5-aromatic and alkyl amino moieties were largely consistent with empirical results. The substitution of a key carboxylate group on the core phenyl ring with tetrazole or truncation of the 5-aryl group reduced affinity. The

  P2Y14受体（P2Y14R）通过激活嗜中性粒细胞的运动来介导炎症活动，但已知的拮抗剂种类却很少。我们已经研究了3-（4-苯基-1 H-1,2,3-三唑-1-基）-5-（芳基）苯甲酸拮抗剂支架的结构-活性关系，并通过对接和分子动力学来辅助（ MD）在P2Y14R同源性模型上进行仿真。使用高吞吐量MD Python环境的计算管道指导了模拟设计。候选物的选择基于配体-蛋白质的形状和互补性以及配体-蛋白质相互作用随时间的持久性。与噻吩有利地取代5-苯基和在5-芳族和烷基氨基之间插入3-亚甲基间隔基的预测在很大程度上与实验结果一致。核心苯环上的关键羧酸酯基团被四唑取代或5-芳基基团的截短降低了亲和力。使用荧光测定法，最有效的拮抗剂是伯3-氨基丙基同类物20（MRS4458）和苯基对甲酰胺30（MRS4478）。
• [EN] HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DU RÉCEPTEUR P2Y14
  申请人：US HEALTH

  公开号：WO2019157417A1

  公开（公告）日：2019-08-15

  Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.

  揭示了以下化合物的结构式（I）-（IX），用于治疗或预防对P2Y14R受体激动剂拮抗敏感的哺乳动物患者的疾病或紊乱，其中R1-R8、X、Y、Z、X'、Y'、Z'和A的定义如下，这些化合物可用于治疗炎症性疾病，如哮喘、囊性纤维化和肾脏的无菌性炎症。
• The identification of 4,7-disubstituted naphthoic acid derivatives as UDP-competitive antagonists of P2Y14
  作者：Jacques Yves Gauthier、Michel Belley、Denis Deschênes、Jean-François Fournier、Sébastien Gagné、Yves Gareau、Martine Hamel、Martin Hénault、Huda Hyjazie、Stacia Kargman、Geneviève Lavallée、Jean-François Levesque、Lianhai Li、Yaël Mamane、Joseph Mancini、Nicolas Morin、Erin Mulrooney、Joël Robichaud、Michel Thérien、Geoffrey Tranmer、Zhaoyin Wang、Jin Wu、W. Cameron Black

  DOI：10.1016/j.bmcl.2011.03.081

  日期：2011.5

  A weak, UDP-competitive antagonist of the pyrimidinergic receptor P2RY14 with a naphthoic acid core was identified through high-throughput screening. Optimization provided compounds with improved potency but poor pharmacokinetics. Acylglucuronidation was determined to be the major route of metabolism. Increasing the electron-withdrawing nature of the substituents markedly reduced glucuronidation and

  通过高通量筛选，鉴定出具有萘甲酸核心的嘧啶能受体P2RY 14的弱，UDP竞争性拮抗剂。优化后的化合物具有更高的效能，但药代动力学较差。酰基葡萄糖醛酸化被确定为新陈代谢的主要途径。增加取代基的吸电子性质可显着减少葡萄糖醛酸苷化并改善药代动力学特征。进一步的优化导致鉴定出化合物38，该化合物是具有良好药代动力学特征的P2Y 14的8 nM UDP竞争性拮抗剂。
• SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY
  申请人：Belley Michel

  公开号：US20100298347A1

  公开（公告）日：2010-11-25

  Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.

  具有以下结构式的2-萘甲酸替代物是GPR105蛋白生物活性的拮抗剂，对于治疗、控制或预防对此受体的拮抗作用有响应的疾病非常有效，包括糖尿病，特别是2型糖尿病，胰岛素抵抗，高血糖，脂质异常，肥胖症，动脉粥样硬化以及与代谢综合征相关的疾病。